 | Up a level |
2019
Wuelfing, C., Boegemann, M., Goebell, P. J., Hammerer, P., Machtens, S., Pfister, D., Schwentner, C., Steuber, T., von Amsberg, G. and Schostak, M. (2019). Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine. Urologe, 58 (9). S. 1066 - 1073. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
2018
Heidenreich, A., Carl, S., Feyerabend, S., Gleissner, J., Gruellich, C., Heinrich, B., Merseburger, A., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Go, J., Golsorkhi, T., Abida, W. and Scher, H. I. (2018). TRITON2: An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 75 - 76. BASEL: KARGER. ISSN 2296-5262
Merseburger, A., Carl, S., Feyerabend, S., Gleissner, J., Grimm, M. -O., Gruellich, C., Heidenreich, A., Heinrich, B., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Passler, L., Shetty, S., Golsorkhi, T., Ryan, C. and Chowdhury, S. (2018). TRITON3: An International, Randomised, Open-Label Phase 3 Study of the PARP Inhibitor Rucaparib vs Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associate with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 74 - 75. BASEL: KARGER. ISSN 2296-5262
2016
Thomas, C., Boegemann, M., Koenig, F., Machtens, S., Schostak, M., Steuber, T. and Heidenreich, A. (2016). Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen. Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel. Urologe, 55 (6). S. 772 - 783. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563